FFR Versus IVUS with Angiography-Derived FFR for Clinical Outcomes in Patients with Coronary Artery Disease
FLAVOUR III
Comparison of Fractional Flow Reserve-Guided Strategy Versus Intravascular Ultrasound-Guided Stent Implantation After Angiography-Derived Fractional Flow Reserve-based Decision-Making (The FLAVOUR III Trial)
1 other identifier
interventional
1,942
2 countries
25
Brief Summary
To compare the clinical outcomes of fractional flow reserve (FFR)-guided strategy versus intravascular ultrasound (IVUS)-guided stent implantation after angiography-derived FFR-based decision-making.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable coronary-artery-disease
Started Mar 2024
Longer than P75 for not_applicable coronary-artery-disease
25 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 27, 2023
CompletedFirst Posted
Study publicly available on registry
January 23, 2024
CompletedStudy Start
First participant enrolled
March 13, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2029
February 24, 2025
September 1, 2024
3.7 years
November 27, 2023
February 20, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Patient-oriented composite outcome
Patient-oriented composite outcome (POCO), defined as a composite of all death, myocardial infarction (MI), or any revascularization at 24 months after randomization.
24 months
Secondary Outcomes (12)
Patient-oriented composite outcome at 60 months
60 months
Individual component of Patient-oriented composite outcome
24 and 60 months
Target vessel failure
24 and 60 months
Cost-effectiveness analysis
24 and 60 months
All-cause and cardiac death
24 and 60 months
- +7 more secondary outcomes
Study Arms (2)
Experimental group
EXPERIMENTALThe percutaneous coronary intervention will be performed by intravascular ultrasound (IVUS)-guided strategy after angiography-derived FFR-based decision-making.
Control group
ACTIVE COMPARATORThe percutaneous coronary intervention will be performed by fractional flow reserve (FFR)-guided strategy.
Interventions
The percutaneous coronary intervention will be performed by intravascular ultrasound (IVUS)-guided strategy after angiography-derived FFR-based decision-making: 1. PCI will be performed if angiography-derived FFR ≤0.80 and will be deferred if angiography-derived FFR \>0.80. 2. If PCI is performed, PCI optimization using IVUS will be performed following the recommended criteria: ① Plaque burden at stent edge ≤55%; ② Minimal stent area ≥ 5.5 mm2, or minimal stent area ≥ distal reference lumen area
The percutaneous coronary intervention will be performed by fractional flow reserve (FFR)-guided strategy: 1. PCI will be performed if FFR ≤0.80 and will be deferred if FFR \>0.80. 2. If PCI is performed, PCI optimization using FFR will be performed following the recommended criteria: ① Post-PCI FFR ≥ 0.88, or ② Post-PCI ΔFFR (\[FFR at stent distal edge\] - \[FFR at stent proximal edge\]) \< 0.05
Eligibility Criteria
You may qualify if:
- Subject must be ≥ 19 years.
- Subject is able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving invasive physiologic or imaging evaluation and PCI with a drug-eluting stent (DES) and he/she or his/her legally authorized representative provides written informed consent.
- Subjects suspected with ischemic heart disease.
- Subjects with coronary artery diameter stenosis 50-90% by angiography-based visual estimation eligible for stent implantation.
- Target vessel size ≥ 2.5mm in visual estimation.
You may not qualify if:
- Known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Prasugrel, Ticagrelor
- Active pathologic bleeding.
- Gastrointestinal or genitourinary major bleeding within the prior 3 months.
- History of bleeding diathesis, known coagulopathy.
- Non-cardiac co-morbid conditions with life expectancy \< 2 years.
- Target lesion located in coronary arterial bypass graft.
- Left main coronary artery stenosis ≥ 50%.
- Chronic total occlusion in the study target vessel.
- Culprit lesion of ST-elevation myocardial infarction (STEMI).
- Not eligible for angiography-derived FFR (ostial RCA ≥ 50% stenosis, severe tortuosity, severe overlap, poor image quality).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Second Affiliated Hospital, School of Medicine, Zhejiang Universitylead
- Seoul National University Hospitalcollaborator
- Peking University Third Hospitalcollaborator
- RenJi Hospitalcollaborator
- Second Affiliated Hospital of Shantou University Medical Collegecollaborator
- The First Affiliated Hospital of Nanchang Universitycollaborator
- First Affiliated Hospital of Kunming Medical Universitycollaborator
- The Fourth People's Hospital of Jinancollaborator
- Jinhua Central Hospitalcollaborator
- The Affiliated Hospital of Hangzhou Normal Universitycollaborator
- Changxing People's Hospitalcollaborator
- First Affiliated Hospital of Wenzhou Medical Universitycollaborator
- The Affiliated Hospital of Medical College, Ningbo Universitycollaborator
- Keimyung University Dongsan Medical Centercollaborator
- Inje University Ilsan Paik Hospitalcollaborator
- Ulsan University Hospitalcollaborator
- Uijeongbu Eulji Medical Centercollaborator
- Kyungpook National University Hospitalcollaborator
- Seoul St. Mary's Hospitalcollaborator
- Yonsei University Wonju Severance Hospitalcollaborator
- Inje University Haeundae Paik Hospitalcollaborator
- Sejong General Hospitalcollaborator
- Chonnam National University Hospitalcollaborator
- Ningbo Medical Center Lihuili Hospitalcollaborator
- The Affiliated Hospital of Shandong University of TCMcollaborator
Study Sites (25)
Peking University Third Hospital
Beijing, China
Second Affiliated Hospital of Shantou University Medical College
Guangdong, China
The Affiliated Hospital of Hangzhou Normal University
Hangzhou, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
Changxing People's Hospital
Huzhou, China
The Affiliated Hospital of Shandong University of TCM
Jinan, China
The Fourth People's Hospital of Jinan
Jinan, China
Jinhua Central Hospital
Jinhua, China
First Affiliated Hospital of Kunming Medical University
Kunming, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
Ningbo Medical Center Lihuili Hospital
Ningbo, China
The Affiliated Hospital of Medical College, Ningbo University
Ningbo, China
Renji Hospital Shanghai Jiaotong University School of Medicine
Shanghai, China
The First Affiliated hospital of Wenzhou Medical University
Wenzhou, China
Bucheon Sejong Hospital
Bucheon-si, South Korea
Inje University Haeundae Paik Hospital
Busan, South Korea
Keimyung University Dongsan Medical Center
Daegu, South Korea
Kyungpook National University Hospital
Daegu, South Korea
Chonnam National University Hospital
Donggu, South Korea
Inje University Ilsan Paik Hospital
Goyang, South Korea
Seoul National University Hospital,
Seoul, South Korea
Seoul ST. Mary's Hospital
Seoul, South Korea
Uijeongbu Eulji Medical Center
Uijeongbu-si, South Korea
Ulsan University Hospital
Ulsan, South Korea
Yonsei University Wonju Severance Hospital
Wŏnju, South Korea
Related Publications (10)
Kogame N, Ono M, Kawashima H, Tomaniak M, Hara H, Leipsic J, Andreini D, Collet C, Patel MR, Tu S, Xu B, Bourantas CV, Lerman A, Piek JJ, Davies JE, Escaned J, Wijns W, Onuma Y, Serruys PW. The Impact of Coronary Physiology on Contemporary Clinical Decision Making. JACC Cardiovasc Interv. 2020 Jul 27;13(14):1617-1638. doi: 10.1016/j.jcin.2020.04.040.
PMID: 32703589BACKGROUNDWriting Committee Members; Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE, Gaudino MF, Goldberger ZD, Grant MC, Jaswal JB, Kurlansky PA, Mehran R, Metkus TS Jr, Nnacheta LC, Rao SV, Sellke FW, Sharma G, Yong CM, Zwischenberger BA. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022 Jan 18;79(2):e21-e129. doi: 10.1016/j.jacc.2021.09.006. Epub 2021 Dec 9.
PMID: 34895950BACKGROUNDRaber L, Mintz GS, Koskinas KC, Johnson TW, Holm NR, Onuma Y, Radu MD, Joner M, Yu B, Jia H, Meneveau N, de la Torre Hernandez JM, Escaned J, Hill J, Prati F, Colombo A, di Mario C, Regar E, Capodanno D, Wijns W, Byrne RA, Guagliumi G; ESC Scientific Document Group. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Eur Heart J. 2018 Sep 14;39(35):3281-3300. doi: 10.1093/eurheartj/ehy285.
PMID: 29790954BACKGROUNDDe Maria GL, Garcia-Garcia HM, Scarsini R, Hideo-Kajita A, Gonzalo Lopez N, Leone AM, Sarno G, Daemen J, Shlofmitz E, Jeremias A, Tebaldi M, Bezerra HG, Tu S, Lemos PA, Ozaki Y, Dan K, Collet C, Banning AP, Barbato E, Johnson NP, Waksman R. Novel Indices of Coronary Physiology: Do We Need Alternatives to Fractional Flow Reserve? Circ Cardiovasc Interv. 2020 Apr;13(4):e008487. doi: 10.1161/CIRCINTERVENTIONS.119.008487. Epub 2020 Apr 16.
PMID: 32295416BACKGROUNDScoccia A, Tomaniak M, Neleman T, Groenland FTW, Plantes ACZD, Daemen J. Angiography-Based Fractional Flow Reserve: State of the Art. Curr Cardiol Rep. 2022 Jun;24(6):667-678. doi: 10.1007/s11886-022-01687-4. Epub 2022 Apr 18.
PMID: 35435570BACKGROUNDCollet C, Onuma Y, Sonck J, Asano T, Vandeloo B, Kornowski R, Tu S, Westra J, Holm NR, Xu B, de Winter RJ, Tijssen JG, Miyazaki Y, Katagiri Y, Tenekecioglu E, Modolo R, Chichareon P, Cosyns B, Schoors D, Roosens B, Lochy S, Argacha JF, van Rosendael A, Bax J, Reiber JHC, Escaned J, De Bruyne B, Wijns W, Serruys PW. Diagnostic performance of angiography-derived fractional flow reserve: a systematic review and Bayesian meta-analysis. Eur Heart J. 2018 Sep 14;39(35):3314-3321. doi: 10.1093/eurheartj/ehy445.
PMID: 30137305BACKGROUNDFearon WF, Achenbach S, Engstrom T, Assali A, Shlofmitz R, Jeremias A, Fournier S, Kirtane AJ, Kornowski R, Greenberg G, Jubeh R, Kolansky DM, McAndrew T, Dressler O, Maehara A, Matsumura M, Leon MB, De Bruyne B; FAST-FFR Study Investigators. Accuracy of Fractional Flow Reserve Derived From Coronary Angiography. Circulation. 2019 Jan 22;139(4):477-484. doi: 10.1161/CIRCULATIONAHA.118.037350.
PMID: 30586699BACKGROUNDXu B, Tu S, Qiao S, Qu X, Chen Y, Yang J, Guo L, Sun Z, Li Z, Tian F, Fang W, Chen J, Li W, Guan C, Holm NR, Wijns W, Hu S. Diagnostic Accuracy of Angiography-Based Quantitative Flow Ratio Measurements for Online Assessment of Coronary Stenosis. J Am Coll Cardiol. 2017 Dec 26;70(25):3077-3087. doi: 10.1016/j.jacc.2017.10.035. Epub 2017 Oct 31.
PMID: 29101020BACKGROUNDKoo BK, Hu X, Kang J, Zhang J, Jiang J, Hahn JY, Nam CW, Doh JH, Lee BK, Kim W, Huang J, Jiang F, Zhou H, Chen P, Tang L, Jiang W, Chen X, He W, Ahn SG, Yoon MH, Kim U, Lee JM, Hwang D, Ki YJ, Shin ES, Kim HS, Tahk SJ, Wang J; FLAVOUR Investigators. Fractional Flow Reserve or Intravascular Ultrasonography to Guide PCI. N Engl J Med. 2022 Sep 1;387(9):779-789. doi: 10.1056/NEJMoa2201546.
PMID: 36053504BACKGROUNDGotberg M, Christiansen EH, Gudmundsdottir IJ, Sandhall L, Danielewicz M, Jakobsen L, Olsson SE, Ohagen P, Olsson H, Omerovic E, Calais F, Lindroos P, Maeng M, Todt T, Venetsanos D, James SK, Karegren A, Nilsson M, Carlsson J, Hauer D, Jensen J, Karlsson AC, Panayi G, Erlinge D, Frobert O; iFR-SWEDEHEART Investigators. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. N Engl J Med. 2017 May 11;376(19):1813-1823. doi: 10.1056/NEJMoa1616540. Epub 2017 Mar 18.
PMID: 28317438BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jian'an Wang, MD, PhD
Second Affiliated Hospital, School of Medicine, Zhejiang University
- PRINCIPAL INVESTIGATOR
Bon-Kwon Koo, MD, PhD
Seoul National University Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 27, 2023
First Posted
January 23, 2024
Study Start
March 13, 2024
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
December 1, 2029
Last Updated
February 24, 2025
Record last verified: 2024-09
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- Data will be available within 12 months of study completion.
- Access Criteria
- Data access requests will be reviewed by an external Independent Review Panel. Requestors will be required to sign a Data Access Agreement
The deidentified data will be shared after publication of first manuscript